Am­gen's Ote­zla notch­es an­oth­er PhI­II win; Califf earns ad­vo­ca­cy group­s' stamp of ap­proval

Am­gen’s block­buster Ote­zla just racked up an­oth­er Phase III win as it looks to con­tin­ue ex­pand­ing on its multi­bil­lion-dol­lar rev­enue stream.

The drug hit the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER